Immunization with thyroglobulin induces Graves'-like disease in mice by Endo, Toyoshi & Kobayashi, Tetsuro
Immunization with thyroglobulin induces Graves’-like disease in mice
Toyoshi Endo* and Tetsuro Kobayashi*
Third Department of Internal Medicine, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Chuo City,
Yamanashi 409-3898, Japan
(Correspondence should be addressed to T Endo; Email: endot@yamanashi.ac.jp)
*(T Endo and T Kobayashi contributed equally to this work)
Abstract
We immunized AKR/N mice with bovine thyroglobulin
(Tg) once every 2 weeks and monitored their time-
dependent changes in
125I uptake activity in the thyroid
glands. After 3 months, anti-Tg antibody was positive in all
sera from the immunized mice. Serum free tri-iodothyronine
(T3) and free thyroxine (T4) levels in the immunized mice
(nZ6) were signiﬁcantly higher than those in the saline
injected (control) mice (nZ6). Neck counts as well as
scintigraphy of the thyroid glands revealed that iodide uptake
activity of the immunized mice was not suppressed, but was
instead higher than that of the control mice. Two of the six
immunized mice showed extremely high iodide uptake
activity. The thyroid glands of these two mice were diffusely
enlarged and the height of the epithelial cells was also
increased. In addition, two mice with high iodide uptake
activity produced a high titer of thyroid-stimulating antibody.
Additional experiments showed that 4 out of 11 AKR/N
mice and 3 out of 10 C57BL6 mice immunized with Tg had
high serum free T3/free T4 levels, high
125I uptake activity of
the thyroid, and positive thyroid-stimulating antibody
activity. Diffuse goiter, thyrotoxicosis, high iodide uptake
activity, and positive thyroid-stimulating antibody are the
characteristics of Graves’ disease. Thus, these mice exhibit
the symptoms of Graves’ disease. These results suggest that
immunization with Tg induces Graves’-like disease in mice
and that our methods will provide a new animal model of
Graves’ disease.
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Introduction
Both Graves’ disease and chronic autoimmune thyroiditis
belong to the family of autoimmune thyroid diseases.
However, Graves’ disease may precede or follow chronic
autoimmune thyroiditis in the same patient, presumably
related by similar autoimmune processes (Kasagi et al. 1993).
Chronic autoimmune thyroiditis is characterized by serum
autoantibodies against thyroglobulin (Tg) and thyroid
peroxidase (TPO), and histologically by ﬁbrosis and varying
degrees of lymphocytic inﬁltration in the thyroid (Dayan &
Daniels 1996). The appearance of MHC class II molecules on
thyroid cells which has been correlated with g-interferon-
containing T cells (Bottazzo et al. 1983), has been thought to
be the initiating factor in chronic autoimmune thyroiditis
(Hamilton et al. 1991). Patients with Graves’ disease also
produce autoantibodies against Tg and TPO, and the disease
is characterized by thyroid-stimulating autoantibody (TSAb)
against thyrotropin receptor (TSHR). This functional
autoantibody stimulates hormone synthesis, secretion, and
cell growth, and induces thyrotoxicosis and goiter in the
disease (Kohn & Shifrin 1982). However, the precise
mechanisms in which TSHR peptides are presented as
antigens still remain unclear.
Shimojo et al. (1996) succeeded in producing a mouse
model of Graves’ disease by immunization with ﬁbroblasts
expressing both TSHR and MHC class II molecules, after
they clearly demonstrated that co-expression of MHC class II
molecule and TSHR on the cell surface were necessary for
producing TSAb in AKR/N mice. Therefore, clariﬁcation of
the conditions or the environments that induce aberrant
expression of MHC class II molecules in the antigen-
presenting cells are important for understanding the
pathogenesis of Graves’ disease.
We hypothesize here that pathological conditions such as
autoimmune thyroiditis and lymphocytic inﬁltration in
thyroid glands must precede the production of TSAb. Thus,
we have produced experimental autoimmune thyroiditis in
mice by immunizing them with Tg and we monitored the
iodide uptake activity of their thyroid glands. We found that
some of them exhibited the symptoms of Graves’ disease.
Materials and methods
Animals and immunization with Tg
All studies performed were approved by the Animal Research
Committee, Yamanashi University. Female AKR/N mice
and C57BL6 mice were obtained from CLEA Japan, Inc.,
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checked for pathogens once every 2 months. All mice were
12–14 weeks old at the beginning of the experiments. Bovine
Tg (0.5 mg/ml) purchased from Sigma–Aldrich Chemical
Co. or saline was emulsiﬁed with the same volume of
complete Freund’s adjuvant (Wako Chemical Co., Tokyo,
Japan) and then 50 ml emulsion (25 mg of Tg/mouse) was
injected into the soleus muscle once every 2 weeks.
All immunizations were performed in the presence of
complete Freund’s adjuvant.
125I uptake and measurement of thyroid hormones
125I–Na (3.7 GBq/ml) was obtained from GE Healthcare,
Japan. The solution was at ﬁrst diluted with sterile saline
to 9.25!10
4 Bq/100 ml. In experiment 1, 100 ml of this
diluted solution was administrated into the peritoneal space at
1–3 months after the ﬁrst immunization. After 24 h, the
mice were anesthetized with pentobarbital and the iodide
uptake into the thyroidglandswasmonitoredby neck counter
and scintigraphy. In experiments 2 and 3, we did not carry
out the monitoring of thyroid iodide uptake activities.
At 3 months after the ﬁrst immunization, accurate radio-
activity of the resected thyrotracheal unit was also measured
with a gamma-counter (Aloka, Autowell Gamma System,
Model ARC-380, Tokyo, Japan) in all experiments. Serum
free thyroxine (T4) and freetri-iodothyronine (T3) levelswere
assayed by an ECLusis system (Roche Diagnostic Co).
Detection of anti-Tg antibody and assay for thyroid-stimulating
antibody activity
Detection of antibody against Tg and TPO was carried out
with a commercial detection kit (Cosmic Co., Tokyo, Japan).
For measuringTSAbactivity,mouseIgGwaspartiallypuriﬁed
with polyethylene glycol and the activity was assayed using a
commercial kit for TSAb (Yamasa Shoyu Co., Chiba, Japan).
Thyroid-stimulating antibody activity (%) was calculated as
follows: (cAMP increase by test IgG/cAMP increase by
control IgG)!100, as previously described (Ohmori et al.
1991). The cut-off value was set as 180%.
Results
We divided female AKR/N mice into three groups
(experiment 1). The ﬁrst group was non-treated (nZ6); the
second group (nZ6) was immunized with bovine Tg and
the third (nZ6) was injected with saline once every 2 weeks;
the
125I uptake activity of their thyroid glands was then
measured by neck counts (Fig. 1a). At 1 month after the ﬁrst
immunization, no signiﬁcant difference in iodide uptake
activity was observed between these three groups. Although
no signiﬁcant difference in the mean uptake activity between
the groups was found at 2 months, mouse No. 1 in the
immunized group showed high iodide uptake activity and
this gradually increased. At 3 months, two out of six mice
immunized with Tg showed higher iodide uptake activity
than those of the other four mice in the same group.
Thyroid scintigraphy carried out at that time also demon-
strated that
125I uptake activity of the thyroid glands in mice
No. 1 and No. 2 in the Tg immunized group was higher
than those of the other four mice of the same group and
also higher than those of the non-treated or saline injected
mice (Fig. 1b).
Three months after the ﬁrst immunization, we examined
their thyroid functions, histology of the glands, and presence
of autoantibodies in the sera. Table 1 shows the radioiodide
Figure 1
125I uptake activity in mice immunized with thyroglobu-
lin and control mice. (a) Time-dependent changes in
125I uptake
activity in mice measured with neck counts.
125I–Na was
administered into the peritoneal space of the non-treated mice
(triangles), thyroglobulin immunized mice (ﬁlled circles) and the
saline injected mice (open circles), and after 24 h, the radioactivity
was monitored by neck counts. The activity was indicated as a
percentage of the total counts administered. (b) Scintigraphy
of the thyroid glands was carried out 3 months after the
ﬁrst immunization.
125I–Na was administered to mice in the same
way as in (a). After 24 h, mice were exposed to the imaging plate
for 1 min and the images were then analyzed using BAS 2500
systems (Fujix, Tokyo, Japan). Upper six thyroid images (Nos 1–6)
were those of the control (saline injected) mice, and the lower six
images (Nos 1–6) were those of the Tg immunized mice. White
and black arrows indicate the location of submandibular glands
and thyroid glands respectively.
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gamma counter. The mean iodide uptake of the immunized
mice was signiﬁcantly higher than that of the non-treated or
saline-injected mice (P!0.05). Particularly, radioactivities
from mice No. 1 and No. 2 in the immunized group were
extremely high (4.72!10
6 and 4.82!10
6 c.p.m). Figure 2a
shows that those thyroid glands having high iodide uptake
activity were diffusely enlarged compared with those of the
saline-injected mice. Microscopic examination of the tissues
revealed that the height of the epithelial cells in mice No. 1
and No. 2 was increased, as shown in Fig. 2c, which is a
characteristic feature of Graves’ disease. When we compared
the mean height of 500 epithelial cells from the immunized
mice with that of 500 cells from the saline-injected mice,
the former (6.58G0.08 mm) was signiﬁcantly taller than the
latter (3.03G0.08 mm; Fig. 2e). No prominent lymphocyte
inﬁltration was observed among the tissues. The mean
serum free T3 and free T4 levels of the immunized mice
were signiﬁcantly (P!0.001) higher than those of the
saline-injected mice (Fig. 3). The free T3 levels in mice No.
1 and No. 2 were markedly higher than those of the other
four mice in the Tg immunized group (Fig. 3 and Table 1).
All Tg immunized mice produced anti-Tg antibody in their
sera, but no activity was observed in the non-treated and the
saline-injected mice. None of the mice produced anti-TPO
antibody in their sera (Table 1). Interestingly, the TSAb
values produced by mice No. 1 and No. 2 were 1320 and
391% respectively (Table 1).
Additionally, we immunized 11 AKR/N mice with bovine
Tg, and 3 months later, measured their serum free T3 and free
T4 levels,
125I uptake activity in the thyroid glands, and TSAb
activity (experiment 2). In this experiment, we omitted
monitoring of thyroid iodide uptake activities of mice by
neck counter, so we did not administer
125I at 1 and 2
months after the ﬁrst immunization. The mean serum free T3
and free T4 levels from immunized mice were signiﬁcantly
higher than those of the control mice. The mean
125I uptake
activity in the thyroid glands of the immunized mice (3.68
G0.20!10
6 c.p.m.) was not suppressed, but was instead
higher than that of the control mice (1.99G0.08!10
6
c.p.m). We also observed that 4 out of the 11 immunized mice
with a high serum free T3 level (Tg 4, 6, 8, and 11) possessed
high TSAb activity (Table 1).
To know whether our observation is speciﬁc to the
AKR/N strain, we immunized C57BL6 mice (nZ10) with
bovine Tg using the same protocol (experiment 3). Again, we
obtained the results that mean serum free T3 and free T4 levels
and mean
125I uptake activity in the thyroid glands of the
immunized mice were signiﬁcantly higher than those of the
control mice (Table 1). Mice with high serum free T3 and free
T4 levels exhibited high TSAb activity (Tg 2, 5, and 6),
suggesting that immunization with Tg also produce Graves’-
like disease in C57BL6 mice.
Discussion
There exists a consensus that TSAb plays a central role in the
pathogenesis of Graves’ disease. The autoantibody stimulates
thyroid epithelial cells like TSH and induces thyrotoxicosis
and goiter (Shimojo et al. 1996). We previously reported
the expression of TSHR in fat cells, the level of which is
almost comparable with that in the thyroid (Endo et al. 1995).
Figure 2 Morphological changes of the thyroid glands of mice
immunized with thyroglobulin. (a) Thyroid glands of a mouse
immunized with thyroglobulin (Tg1) are diffusely enlarged.
(b)Control(salineinjected)mouse(S1).(candd)Hematoxylin–eosin
staining of the sections from the immunized mouse (Tg1) (c, !100)
andthecontrolmouse(S1)(d,!100).(e)Heightofepithelialcellsof
theimmunizedmicewiththatofthecontrolmice.Theheightsof500
epithelial cells from control mice and those from immunized mice
were measured after amplifying their digital images. Statistical
analysis was carried out with the Student’s t-test.
Figure 3 Serum free T3 and free T4 levels in mice immunized with
thyroglobulin and saline injected (control) mice. At 3 months after
the ﬁrst immunization, the sera were obtained by heart puncture
and the free T3 (a) and free T4 (b) levels were determined as
described in the Materials and methods section. The values are
indicated as meanGS.E.M.* P!0.05.
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Free T3 (pg/ml) Free T4 (ng/dl)
125I uptake
a
(!10
6 c.p.m.) Anti-Tg (U/ml) Anti-TPO (U/ml) TSAb (%)
Mouse
Exp. 1 AKR/N mice
N1 3.05 0.95 3.98 O0.3 O0.39 6
N2 3.41 .11 4.22 O0.3 O0.3 112
N3 3.21 1.23 3.66 O0.3 O0.3 101
N4 3.42 1.18 4.11 O0.3 O0.38 1
N5 3.50 0.98 3.28 O0.3 O0.3 131
N6 3.35 1.22 3.80 O0.3 O0.38 7
Mean 3.32G0.17 1.1G0.12 3.84G0.38
S1 2.75 0.82 3.73 O0.3 O0.3 100
S2 3.32 1.28 3.73 O0.3 O0.38 4 .8
S3 2.94 1.03 3.62 O0.3 O0.3 114.6
S4 3.37 0.58 3.62 O0.3 O0.3 119.7
S5 2.89 1.04 3.92 O0.3 O0.3 105.3
S6 4.13 1.25 3.78 O0.3 O0.3 122.2
Mean 3.23G0.21 1.00G0.11 3.73G0.05
Tg1 8.90 1.95 4.72 173 O0.3 1320
Tg2 5.45 1.49 4.81 237 O0.3 391
Tg3 4.60 3.16 3.75 131 O0.3 104
Tg4 4.08 2.68 3.92 159 O0.3 106
Tg5 4.64 5.46 3.83 187 O0.3 111
Tg6 3.93 2.51 3.76 54 O0.39 9
Mean 5.27G0.76* 2.81G0.58* 4.13G0.20
†
Exp. 2 AKR/N mice
S1 1.39 1.72 1.85 O0.3 O0.3 110
S2 2.78 1.62 2.34 O0.3 O0.39 7
S3 3.21 1.88 1.73 O0.3 O0.3 101
S4 3.42 1.59 2.22 O0.3 O0.38 1
S5 3.50 1.42 2.48 O0.3 O0.39 9
S6 2.89 0.82 1.71 O0.3 O0.3 121
S7 3.05 1.05 1.82 O0.3 O0.38 5
S8 3.11 0.91 2.01 O0.3 O0.3 102
S9 2.88 1.22 1.89 O0.3 O0.3 112
S10 2.76 1.29 1.92 O0.3 O0.3 103
Mean 2.90G0.18 1.35G0.11 1.99G0.08
Tg1 4.83 1.94 2.79 117 O0.3 138
Tg2 5.20 3.45 3.35 160 O0.3 158
Tg3 5.38 2.25 3.07 151 O0.3 181
Tg4 12.11 6.34 .95 210 O0.3 435
Tg5 4.21 2.01 3.01 162 O0.39 4
Tg6 19.09 4.76 4.73 117 O0.3 690
Tg7 4.01 2.21 3.43 97 O0.3 106
Tg8 6.46 3.68 3.64 69 O0.3 321
Tg9 4.03 2.44 3.45 18.5 O0.3 128
Tg10 4.52 3.83 3.66 172 O0.3 169
Tg11 5.93 3.29 3.87 52 O0.3 356
Mean 6.88G1.40
† 3.28G0.41* 3.68G0.20*
Exp. 3 C57BL6/N mice
S1 2.51 1.45 2.35 O0.3 O0.3 101
S2 2.83 1.15 1.95 O0.3 O0.3 125
S3 2.51 1.34 1.48 O0.3 O0.3 111
S4 2.36 1.38 1.35 O0.3 O0.3 142
S5 3.13 1.31 1.24 O0.3 O0.3 113
S6 2.31 1.17 2.88 O0.3 O0.3 101
S7 2.79 1.22 1.59 O0.3 O0.3 110
S8 2.41 1.28 1.83 O0.3 O0.3 136
S9 2.37 1.27 1.51 O0.3 O0.39 9
S10 3.19 1.53 1.26 O0.3 O0.3 138
Mean 2.65G0.11 1.31G0.04 1.74G0.16
Tg1 2.87 2.00 1.81 45 O0.39 1
Tg2 6.44 4.25 3.80 53 O0.3 760
(continued)
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attributable to the autoantibody against TSHR.
Recently, many groups have developed animal models of
Graves’ disease by immunizing with TSHR peptides (Endo
et al. 1991), TSHR protein (Kaithamana et al. 1999), or
TSHR-expressing ﬁbroblasts (Shimojo et al. 1996), or by
using the expression plasmid of TSHR (Costagliola et al.
2000) and adenovirus-mediated TSHR (Nagayama et al.
2002). All of these data support that TSHR autoantibody is
the cause of Graves’disease. Thus, our next concern was the
antigen-presenting mechanism of TSHR in its autoimmune
process. From this point of view, Shimojo’s model is
extremely important, because the co-existence of MHC
class II molecules and TSHR on the cell surface of ﬁbroblasts
can produce TSAb in mice, but not the co-existence of MHC
class I molecules and TSHR. The evidence supports the
previous hypothesis that aberrant expression of MHC class II
molecule on thyroid epithelial cells may trigger a cascade of
self-directed, uncontrolled immune response in Graves’
disease (Hanafusa et al. 1983).
However, it is still controversial whether TSHR peptides
are presented as antigens by speciﬁcally antigen-presenting
cells (macrophages) or by other cells (thyroid epithelial cells).
In the former, destructive or degenerative changes of thyroid
epithelial cells may precede the process, and in case of the
latter, inﬁltration of g-interferon containing T cells may
precede the process.
Twarog & Rose (1968) produced experimental auto-
immune thyroiditis in mice by immunizing mice with thyroid
extracts emulsiﬁed with Freund’s complete adjuvant. After
that, this disease has been readily induced in many strains of
mice by immunization with mouse Tg emulsiﬁed in Freund’s
complete adjuvant. In some strains (low responders to Tg),
there is only minor thyroid damage after immunization with
Tg, whereas in other strains (high responders), the thyroid
damage is extensive (Vladutiu & Rose 1971). It is widely
believed that these mouse models of autoimmune thyroiditis
are in a hypothyroid state, but there are few studies of thyroid
function in mice with induced autoimmune thyroiditis.
Vladutiu & Kenney (1985) investigated the thyroid function
of mice immunized with Tg. They found that in all mice
(low and high responders), the lowest levels of T4 were
observed 2 weeks after immunization, and in the fourth
week, T4 concentration was, surprisingly and inexplicably,
higher than the pre-immunization values. We demonstrate
here that immunization of mice with Tg induces thyrotoxi-
cosis. A detailed comparison of our data with that of
Vladutiu & Kenney is difﬁcult because their experimental
conditions and protocols were different from ours, but
thyrotoxicosis might occur after 4 weeks from the ﬁrst
immunization with Tg.
However, iodide uptake activity of Tg immunized
mice was not suppressed, but was instead enhanced, so it is
unlikely that the increase of serum thyroid hormone
levels was merely due to the destruction of thyroid epithelial
cells. The phenomenon was observed not only in AKR/N
mice (high responders) but also in C57BL6 mice (low
responders), suggesting that it is not strain speciﬁc. In
addition, some of the Tg immunized AKR/N mice as well
as C57BL6 mice had high iodide uptake activity and high
titers of TSAb.
To obtain clear thyroid image with short exposure time to
the imaging plate, we administrated 9.25!10
4 Bq of
125It o
each mouse in experiment 1, the dose (4.6 MBq/kg) of
which is almost comparable with that used for therapy for
Graves’disease in human. Recently, it has been reported that
TSAb may occur shortly after radioiodine therapy in toxic
multinodular goiter, in which pre-existing autoimmunity
may not be a requirement for the induction of the antibodies
(Hovens et al.2 0 0 7 ). So the possibility remains that
administration of
125I to mice in the course of experiment 1
might induce TSAb in these mice. However, in experiments
2 and 3, we omitted monitoring of thyroid iodide uptake
activities by neck counter so, we administrated
125I to the
animals only at 3 months point. Thus, we think it likely that
Graves’-like disease in these mice was induced by immuniz-
ation of Tg. It would be important to know whether
immunization with other thyroid antigens such as TPO also
Table 1 Continued
Free T3 (pg/ml) Free T4 (ng/dl)
125I uptake
a
(!10
6 c.p.m.) Anti-Tg (U/ml) Anti-TPO (U/ml) TSAb (%)
Tg3 3.33 2.11 1.76 30 O0.3 177
Tg4 3.03 1.75 2.94 33 O0.3 161
Tg5 6.28 2.21 3.95 37 O0.3 381
Tg6 12.05 3.61 4.34 207 O0.3 654
Tg7 3.14 3.22 2.38 39 O0.38 3
Tg8 3.39 3.38 2.31 44 O0.3 118
Tg9 4.40 2.07 2.26 69 O0.3 113
Tg10 2.31 1.51 1.73 2.7 O0.3 101
Mean 4.72G0.93* 2.61G0.29
† 2.73G0.30*
N, non-treated mice; S, control (saline) mice; Tg, thyroglobulin immunized mice. *P!0.001 versus control (saline) mice.
†P!0.05 versus control (saline) mice.
aRadioactivity of the thyro-tracheal unit measured by a gamma counter.
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suggest that immunization with Tg induces Graves’-like
disease in mice and also that the pathogenesis of two disorders
are closely related.
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